Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 78 results:
Author Title Type [ Year] Filters: Keyword is Non-alcoholic Fatty Liver Disease [Clear All Filters]
Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis..
Hormones (Athens). 22(4), 655-664.
(2023). Impact of nonalcoholic fatty liver disease-related metabolic state on depression..
Neurochem Int. 163, 105484.
(2023). Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities..
Aliment Pharmacol Ther. 57(10), 1186-1187.
(2023). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2022).
(2022). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited..
J Gastrointestin Liver Dis. 29(2), 270-271.
(2020). Selenium and selenoprotein P in nonalcoholic fatty liver disease..
Hormones (Athens). 19(1), 61-72.
(2020). Menopause and its Cardiometabolic Consequences: Current Perspectives..
Curr Vasc Pharmacol. 17(6), 543-545.
(2019). Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort..
Horm Metab Res. 51(2), 134-140.
(2019). Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus..
Curr Pharm Des. 25(18), 2051-2059.
(2019). The significance of paired biopsies in estimating disease progression in patients with nonalcoholic steatohepatitis..
Eur J Gastroenterol Hepatol. 31(7), 897-898.
(2019). Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension..
Curr Vasc Pharmacol. 16(4), 393-400.
(2018). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). Thyroid dysfunction and non-alcoholic fatty liver disease..
Minerva Endocrinol. 43(3), 367-376.
(2018). Adipose tissue, obesity and non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 92-108.
(2017). Current and future treatment options in non-alcoholic steatohepatitis (NASH)..
Expert Rev Gastroenterol Hepatol. 11(4), 357-369.
(2017). Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial..
Diabetes Obes Metab. 19(12), 1805-1809.
(2017). Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 89-91.
(2017). Hypogonadism and non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 145-150.
(2017). Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease..
Aliment Pharmacol Ther. 46(6), 637-638.
(2017). Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia..
Aliment Pharmacol Ther. 45(4), 576-577.
(2017). Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists..
Metabolism. 66, 64-68.
(2017). Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome..
Minerva Endocrinol. 42(2), 122-131.
(2017).